Beta-thalassemia results from mutations of the β-hemoglobin (Hbb) gene and reduced functional Hbb synthesis. Excess α-Hb causes globin chain aggregation, oxidation, cytoskeletal damage, and increased ...

"Vertex reports long-term results for Casgevy in sickle cell and thalassaemia" was originally created and published by ...

Thalassemia is a category of inherited blood disorders, becoming a primary health threat due to its increased prevalence worldwide. Through examination and testing of Thalassemia is widely accessible ...

Genetics plays a crucial role in reproductive medicine, impacting both fertility and the health of offspring. According to ...

In people with beta-thalassaemia, osteoporosis represents an important cause of morbidity and is due to a number of factors. First, ineffective erythropoiesis causes bone marrow expansion, leading to ...

Metro New gene therapy at Cleveland Clinic aims to end transfusions for thalassemia Published: Jun. 23, 2025, 1:28 p.m.

Thalassemia is viewed as a prevalent inherited blood disease that has gotten exorbitant consideration in the field of medical research around the world. Inherited diseases have a high risk that ...

Apple provided developers with the second beta of iOS 26, introducing the first changes and refinements to the new operating system since it debuted after the WWDC keynote. Because we're early in ...

Update June 23: Apple has released iOS 26 beta 2. This is still a developers-only release. The public beta is scheduled to start in July, likely after one or two more developer-only beta releases ...

The update appears to be a minor revision rather than a full beta 2 release. The new build began appearing on some devices on June 12, just three days after iOS 26 beta 1 was first released ...

As you may already know by now, Apple announced iOS 26 at its WWDC keynote this past Monday. This version of iOS contain tons of new features including an all-new Liquid Glass design, new features for ...

These data validate the further development of Editas' proprietary HSC-tLNP for editing of the HBG1/2 promoters for the treatment of sickle cell disease and beta thalassemia,” said Linda C ...